The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Changes in PD-L1 tumor proportion score are associated with CD274 gene (encoding PD-L1) copy number variation in non-small cell lung cancer.
 
Stephanie Leigh Alden
No Relationships to Disclose
 
Biagio Ricciuti
No Relationships to Disclose
 
Giuseppe Lamberti
No Relationships to Disclose
 
Liam Flinn Spurr
Employment - Genzyme (I)
Stock and Other Ownership Interests - Applied Genetic Technologies Corporation; CRISPR Therapeutics; Novavax; Vertex
 
Lynette M. Sholl
Stock and Other Ownership Interests - Moderna Therapeutics (I)
Consulting or Advisory Role - EMD Serono; Genentech
Research Funding - Roche/Genentech
 
Andrew D. Cherniack
Employment - LabCorp (I)
Stock and Other Ownership Interests - Merck
Research Funding - Bayer
 
Mark M. Awad
Consulting or Advisory Role - Abbvie; Achilles Therapeutics; Archer; ARIAD; AstraZeneca; AstraZeneca/MedImmune; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; EMD Serono; Foundation Medicine; Genentech; Gritstone Bio; Hengrui Therapeutics; Maverick Therapeutics; Merck; Mirati Therapeutics; Nektar; Neon Therapeutics; NextCure; Novartis; Panasonic; Pfizer; Syndax
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst)
 
Yvonne Y. Li
No Relationships to Disclose